PDE5 inhibitors have been developed and used for various cancer types, including HNSCC, melanoma, myeloma, prostate cancer, gastrointestinal cancer, and neurologic tumors,253, 254, 255, 256, 257 augmenting antitumor immune responses in cancer‐bearing hosts. Here, PDE5A is linked to cancer.